← Leaderboards
Steven Grant
Virginia Commonwealth University
$20,337,700
Attributed
$31,762,175
Total exposure
34
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,762,175 · 34
By mechanism
UM1$13,989,356 · 1
R01$10,600,421 · 6
R21$3,049,215 · 6
UH2$1,554,073 · 1
RC2$1,181,792 · 1
M01$687,635 · 17
Top collaborators
- Lillian L Siu10 shared
- Philippe Bedard5 shared
- Kevin D Courtney5 shared
- Jeffrey Lancet5 shared
- Devalingam Mahalingam5 shared
- Amit M Oza5 shared
- Daniel M Sullivan5 shared
- Salma Jabbour1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Louis S. Harris$3,757,007
- Cynthia Nau Cornelissen$16,417,118
- Harlan Tonie Wright$500,000
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisBaseClinical ResearchCellsPathway InteractionsPharmacodynamicsInsightFundingLeukemiaMalignant NeoplasmsClinical TrialsMediatingLeadResponseIn VivoLaboratoriesDrug ResistanceDown-RegulationRegimenResistanceBortezomibInhibitor/AntagonistFlavopiridolRefractory
Grant awards (99)
North American Star Consortium$1,720,919
UM1 · FY2025 · CA
North American Star Consortium$920,429
UM1 · FY2024 · CA
North American Star Consortium$2,106,066
UM1 · FY2023 · CA
North American Star Consortium$372,146
UM1 · FY2022 · CA
Developmental Therapeutics Program$87,316
P30 · FY2021 · CA · contact PI
North American Star Consortium$5,963,609
UM1 · FY2020 · CA
Targeting Multiple Myeloma with Smac-mimetics and HDAC Inhibitors$313,959
R01 · FY2020 · CA · contact PI
Developmental Therapeutics Program$71,907
P30 · FY2020 · CA · contact PI
Princess Margaret Phase I Consorium (PMP1C)$529,423
UM1 · FY2019 · CA
Princess Margaret Phase I Consorium (PMP1C)$341,419
UM1 · FY2019 · CA
Targeting Multiple Myeloma with Smac-mimetics and HDAC Inhibitors$304,539
R01 · FY2019 · CA · contact PI
Princess Margaret Phase I Consorium (PMP1C)$99,360
UM1 · FY2019 · CA
Developmental Therapeutics Program$75,424
P30 · FY2019 · CA · contact PI
Princess Margaret Phase I Consorium (PMP1C)$932,981
UM1 · FY2018 · CA
Targeting Multiple Myeloma with Smac-mimetics and HDAC Inhibitors$313,959
R01 · FY2018 · CA · contact PI
Developmental Therapeutics Program$75,323
P30 · FY2018 · CA · contact PI
Developmental Therapeutics Program$12,843
P30 · FY2018 · CA · contact PI
Developmental Therapeutics Program$11,990
P30 · FY2018 · CA · contact PI
Developmental Therapeutics Program$5,070
P30 · FY2018 · CA · contact PI
Wee1 and HDAC inhibition in relapsed/refractory AML$615,403
UH2 · FY2017 · TR · contact PI
Targeting Multiple Myeloma with Smac-mimetics and HDAC Inhibitors$313,959
R01 · FY2017 · CA · contact PI
Targeting AML with PI3K/AKT inhibitors and BH3-mimetics$284,794
R01 · FY2017 · CA · contact PI
Developmental Therapeutics Program$75,121
P30 · FY2017 · CA · contact PI
Princess Margaret Phase I Consorium (PMP1C)$1,003,004
UM1 · FY2016 · CA
Targeting Multiple Myeloma with Smac-mimetics and HDAC Inhibitors$313,959
R01 · FY2016 · CA · contact PI
Targeting AML with PI3K/AKT inhibitors and BH3-mimetics$284,794
R01 · FY2016 · CA · contact PI
Wee1 and HDAC inhibition in relapsed/refractory AML$938,670
UH2 · FY2015 · TR · contact PI
Targeting AML with PI3K/AKT inhibitors and BH3-mimetics$461,477
R01 · FY2015 · CA · contact PI
Targeting AML with PI3K/AKT inhibitors and BH3-mimetics$276,250
R01 · FY2014 · CA · contact PI
Targeting AML with PI3K/AKT inhibitors and BH3-mimetics$284,327
R01 · FY2013 · CA · contact PI
Checkpoint Abrogation and MEK 1/2 Inhibition in Myeloma$227,936
R01 · FY2013 · CA · contact PI
Checkpoint Abrogation and MEK 1/2 Inhibition in Myeloma$242,485
R01 · FY2012 · CA · contact PI
NF-kappaB Inhibitors and Differentiation-Inducers in Leukemia$245,455
R01 · FY2011 · CA · contact PI
Checkpoint Abrogation and MEK 1/2 Inhibition in Myeloma$242,485
R01 · FY2011 · CA · contact PI
Proteasome/HDAC Inhibition in Leukemia/MDS; Phase I Trial and Correlative Studies$589,802
RC2 · FY2010 · CA · contact PI
Phase I Trial of Bortezomib and Romidepsin in CLL and Small Cell Lymphoma$262,278
R21 · FY2010 · CA · contact PI
NF-kappaB Inhibitors and Differentiation-Inducers in Leukemia$253,047
R01 · FY2010 · CA · contact PI
Checkpoint Abrogation and MEK 1/2 Inhibition in Myeloma$248,557
R01 · FY2010 · CA · contact PI
NF-kappaB Inhibitors and Differentiation-Inducers in Leukemia$57,444
R01 · FY2010 · CA · contact PI
PHASE I TRIAL OF BORTEZOMIB AND FLAVOPIRIDOL WITH RECURRENT B-CELL NEOPLASMS$17,396
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: PHASE I TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH FLAVOPIRI$5,799
M01 · FY2010 · RR · contact PI
Proteasome/HDAC Inhibition in Leukemia/MDS; Phase I Trial and Correlative Studies$591,990
RC2 · FY2009 · CA · contact PI
Phase I Trial of Bortezomib and Romidepsin in CLL and Small Cell Lymphoma$274,653
R21 · FY2009 · CA · contact PI
NF-kappaB Inhibitors and Differentiation-Inducers in Leukemia$253,047
R01 · FY2009 · CA · contact PI
Checkpoint Abrogation and MEK 1/2 Inhibition in Myeloma$249,983
R01 · FY2009 · CA · contact PI
CLINICAL TRIAL: PHASE I TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH FLAVOPIRI$125,499
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE I TRIAL OF BORTEZOMIB AND FLAVOPIRIDOL WITH RECURRENT B-CE$120,366
M01 · FY2009 · RR · contact PI
NF-kappaB Inhibitors and Differentiation-Inducers in Leukemia$55,731
R01 · FY2009 · CA · contact PI
Promotion of Nucleoside Analog Induced Apoptosis by HDIs$256,009
R01 · FY2008 · CA · contact PI
NF-kappaB Inhibitors and Differentiation-Inducers in Leukemia$253,047
R01 · FY2008 · CA · contact PI
CLINICAL TRIAL: PHASE I TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH FLAVOPIRI$71,676
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE I TRIAL OF BORTEZOMIB AND FLAVOPIRIDOL WITH RECURRENT B-CE$54,989
M01 · FY2008 · RR · contact PI
Flavopiridol / Bortezomib in Myeloma / B-Cell Neoplasms$37,250
R21 · FY2008 · CA · contact PI
Promotion of Nucleoside Analog Induced Apoptosis by HDIs$256,009
R01 · FY2007 · CA · contact PI
NF-kappaB Inhibitors and Differentiation-Inducers in Leukemia$253,047
R01 · FY2007 · CA · contact PI
PHASE I TRIAL OF BORTEZOMIB AND FLAVOPIRIDOL WITH RECURRENT B-CELL NEOPLASMS$44,948
M01 · FY2007 · RR · contact PI
PHASE I TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH FLAVOPIRIDOL IN PATIENTS$40,734
M01 · FY2007 · RR · contact PI
PHASE I STUDY OF FLAVOPIRIDOL WITH IMATINIB MESYLATE (STI1571, GLEEVEC)$351
M01 · FY2007 · RR · contact PI
Promotion of Nucleoside Analog Induced Apoptosis by HDIs$263,655
R01 · FY2006 · CA · contact PI
CDK/histone deacetylase inhibition in acute leukemia$251,828
R21 · FY2006 · CA · contact PI
Checkpoint abrogation and MEK1/2 inhibition in myeloma$243,515
R01 · FY2006 · CA · contact PI
PHASE I TRIAL OF BORTEZOMIB AND FLAVOPIRIDOL WITH RECURRENT B-CELL NEOPLASMS$33,199
M01 · FY2006 · RR · contact PI
PHASE I STUDY OF FLAVOPIRIDOL WITH IMATINIB MESYLATE (STI1571, GLEEVEC)$12,964
M01 · FY2006 · RR · contact PI
CDK/histone deacetylase inhibition in acute leukemia$277,243
R21 · FY2005 · CA
Promotion of Nucleoside Analog Induced Apoptosis by HDIs$267,470
R01 · FY2005 · CA
Checkpoint abrogation and MEK1/2 inhibition in myeloma$249,375
R01 · FY2005 · CA
Flavopiridol and differentiation-inducers in leukemia$249,375
R01 · FY2005 · CA
Flavopiridol / Bortezomib in Myeloma / B-Cell Neoplasms$213,629
R21 · FY2005 · CA
PHASE I TRIAL OF BORTEZOMIB AND FLAVOPIRIDOL WITH RECURRENT B-CELL NEOPLASMS$39,363
M01 · FY2005 · RR
BRYOSTATIN &FLUDARABINE IN LYMPHOCYTIC LEUKEMIA &NON-HODGKIN'S LYMPHOMA$26,737
M01 · FY2005 · RR
PHASE I STUDY OF FLAVOPIRIDOL WITH IMATINIB MESYLATE (STI1571, GLEEVEC)$15,968
M01 · FY2005 · RR
Flavopiridol and Imatinib in Bcr/Abl+ Leukemia$271,299
R21 · FY2004 · CA
Promotion of Nucleoside Analog Induced Apoptosis by HDIs$270,000
R01 · FY2004 · CA
Flavopiridol and differentiation-inducers in leukemia$249,375
R01 · FY2004 · CA
Checkpoint abrogation and MEK1/2 inhibition in myeloma$249,375
R01 · FY2004 · CA
Flavopiridol / Bortezomib in Myeloma / B-Cell Neoplasms$231,985
R21 · FY2004 · CA
Bryostatin &Fludarabine in Lymphocytic Leukemia &Non-Hodgkin's Lymphoma$76,496
M01 · FY2004 · RR
Phase I Study of Flavopiridol with Imatinib Mesylate$251
M01 · FY2004 · RR
Bryostatin and HiDAC in patients with refract. Leukemia$251
M01 · FY2004 · RR
Flavopiridol and Imatinib in Bcr/Abl+ Leukemia$297,053
R21 · FY2003 · CA
Checkpoint abrogation and MEK1/2 inhibition in myeloma$292,275
R01 · FY2003 · CA
Flavopiridol and differentiation-inducers in leukemia$249,375
R01 · FY2003 · CA
POTENTIATION OF TAXANE ACTIVITY BY MEK/MAPK INHIBITORS$168,863
R01 · FY2003 · CA
Phase II and Correlative Studies of Bryo/HiDAC$321,390
R21 · FY2002 · CA
MODULATION OF ARA-C INDUCED APOPTOSIS BY BRYOSTATIN 1$314,725
R01 · FY2002 · CA
Flavopiridol and differentiation-inducers in leukemia$249,375
R01 · FY2002 · CA
POTENTIATION OF TAXANE ACTIVITY BY MEK/MAPK INHIBITORS$164,601
R01 · FY2002 · CA
Phase II and Correlative Studies of Bryo/HiDAC$323,820
R21 · FY2001 · CA
MODULATION OF ARA-C INDUCED APOPTOSIS BY BRYOSTATIN 1$272,468
R01 · FY2001 · CA
GENE REGULATION OF IONIZING RADIATION-INDUCED APOPTOSIS$184,121
P01 · FY2001 · CA
POTENTIATION OF TAXANE ACTIVITY BY MEK/MAPK INHIBITORS$160,466
R01 · FY2001 · CA
PHASE I/LABORATORY STUDIES BRYOSTATIN/FLVDARA IN CLL/NHL$143,362
R21 · FY2001 · CA
MODULATION OF ARA-C INDUCED APOPTOSIS BY BRYOSTATIN 1$15,835
R01 · FY2001 · CA
BRYOSTATIN 1 (NSC 339555) &FLUDARABINE IN LYMPHOCYTIC LEUKEMIA$0
M01 · FY2001 · RR
MODULATION OF ARA-C INDUCED APOPTOSIS BY BRYOSTATIN 1$266,018
R01 · FY2000 · CA
POTENTIATION OF TAXANE ACTIVITY BY MEK/MAPK INHIBITORS$157,981
R01 · FY2000 · CA
PHASE I/LABORATORY STUDIES BRYOSTATIN/FLVDARA IN CLL/NHL$143,425
R21 · FY2000 · CA
GENE REGULATION OF IONIZING RADIATION-INDUCED APOPTOSIS$100,568
P01 · FY2000 · CA
BRYOSTATIN 1 (NSC 339555) &FLUDARABINE IN LYMPHOCYTIC LEUKEMIA$648
M01 · FY2000 · RR